Advertisement

Document › Details
InterAx Biotech AG. (1/15/19). "Press Release: InterAx Biotech Closes Financing Round of CHF 3 Million and Appoints New Member of the Board".
InterAx Biotech, pioneering computational pharmacology for drug discovery, has closed a financing round of CHF 3 million. The investment round was led by Falcon III Ventures and investiere. The new funds will be used to accelerate commercialization of the technology platform which enables intelligent drug candidate design and selection.
InterAx appoints Dr. Bettina Ernst as a new member of the board of directors. She brings in additional extensive and valuable experience from the biotech and pharmaceutical industry.
Record changed: 2019-01-22 |
Advertisement

More documents for InterAx Biotech AG
- [1] InterAx Biotech AG. (5/31/18). "Press Release: InterAx Biotech and Vrije Universiteit Amsterdam Enter a Collaboration to Unlock Novel Chemical Space for Chemokine Therapeutics". Villigen & Amsterdam....
- [2] InterAx Biotech AG. (4/18/18). "Press Release: New Immune Oncology Drug Molecules Expected to Result from LeadXpro / InterAx Partnership". Villigen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top